The activated oligomer compounds described herein are capable of forming
bio-reversible covalent bonds with plasma proteins, in particular with
human serum albumin. The plasma protein-oligomer complexes of the present
invention exhibit enhanced cellular entry and significantly enhanced
serum half-life.